Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ACTRN12626001210369) titled 'Bronchoscopic Tumour Ablation for Immune Priming to Enhance Neoadjuvant Chemotherapy and Immunotherapy in Resectable Non-Small Cell Lung Cancer (IMPRINT Study): A Single-Arm Open Label Feasibility Study' on Sept. 30.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Assignment: Single group
Type of endpoint: Safety/efficacy
Primary Sponsor: Royal Melbourne Hospital
Condition:
non-small cell lung cancer
non-small cell lung cancer
Cancer - Lung - Non small cell
Intervention:
This study will determine if bronchoscopic thermal ablati...